KPRX Live signaler | Maksimer profitt med Getagraph.com

KJøP 123104 min ago

@ $0.800

Utstedt: 7 feb 2024 @ 19:05

Avkastning: -32.18%

Forrige signal: feb 7 - 17:44

Forrige signal: Selg

Avkastning: -5.88 %

Live Chart Being Loaded With Signals

Commentary (2 mai 2024 @ 22:00):

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States...

Stats
Dagens volum	53 021.00
Gjennomsnittsvolum	356 283
Markedsverdi	14.25M
EPS	$-0.470 ( 2024-03-28 )
Neste inntjeningsdato	( $-0.420 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.200
ATR14	$0.00800 (1.47%)

Insider Trading

Date	Person	Action	Amount	type
2023-09-29	Tosca Melissa	Buy	60 000	Stock Option (right to buy)
2023-09-29	Tosca Melissa	Buy	30 000	Common Stock
2023-09-29	Daniels Eric Joseph	Buy	125 000	Stock Option (right to buy)
2023-09-29	Daniels Eric Joseph	Buy	62 500	Common Stock
2023-09-29	Strem Brian M.	Buy	150 000	Stock Option (right to buy)

INSIDER POWER
100.00
Last 91 transactions
Buy: 1 933 640 \| Sell: 3 426 001

Kiora Pharmaceuticals, Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Kiora Pharmaceuticals, Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-62 424.00 (0.00 %)
EPS:	$-2.58

FY	2023
Omsetning:	$0
Bruttogevinst:	$-62 424.00 (0.00 %)
EPS:	$-2.58

FY	2022
Omsetning:	$0
Bruttogevinst:	$-134 028 (0.00 %)
EPS:	$-18.55

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-143.31

Financial Reports:

No articles found.

Kiora Pharmaceuticals,

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.

Sanntidsoppdatering for Kiora Pharmaceuticals, [KPRX]

Upcoming Earnings Alert